|
1
|
Richardson PG, Mitsiades C, Hideshima T
and Anderson KC: Bortezomib: Proteasome inhibition as an effective
anticancer therapy. Annu Rev Med. 57:33–47. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roccaro AM, Hideshima T, Raje N, Kumar S,
Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, et
al: Bortezomib mediates antiangiogenesis in multiple myeloma via
direct and indirect effects on endothelial cells. Cancer Res.
66:184–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen D, Frezza M, Schmitt S, Kanwar J and
Dou QP: Bortezomib as the first proteasome inhibitor anticancer
drug: Current status and future perspectives. Curr Cancer Drug
Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaluz S, Kaluzová M and Stanbridge EJ:
Proteasomal inhibition attenuates transcriptional activity of
hypoxia-inducible factor 1 (HIF-1) via specific effect on the
HIF-1alpha C-terminal activation domain. Mol Cell Biol.
26:5895–5907. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shin DH, Chun YS, Lee DS, Huang LE and
Park JW: Bortezomib inhibits tumor adaptation to hypoxia by
stimulating the FIH-mediated repression of hypoxia-inducible
factor-1. Blood. 111:3131–3136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Talks KL, Turley H, Gatter KC, Maxwell PH,
Pugh CW, Ratcliffe PJ and Harris AL: The expression and
distribution of the hypoxia-inducible factors HIF-1alpha and
HIF-2alpha in normal human tissues, cancers and tumor-associated
macrophages. Am J Pathol. 157:411–421. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tian H, McKnight SL and Russell DW:
Endothelial PAS domain protein 1 (EPAS1), a transcription factor
selectively expressed in endothelial cells. Genes Dev. 11:72–82.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu CJ, Wang LY, Chodosh LA, Keith B and
Simon MC: Differential roles of hypoxia-inducible factor 1alpha
(HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell
Biol. 23:9361–9374. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kaluz S, Kaluzová M, Liao SY, Lerman M and
Stanbridge EJ: Transcriptional control of the tumor- and
hypoxia-marker carbonic anhydrase 9: A one transcription factor
(HIF-1) show? Biochim Biophys Acta. 1795:162–172. 2009.PubMed/NCBI
|
|
10
|
Hu CJ, Sataur A, Wang L, Chen H and Simon
MC: The N-terminal transactivation domain confers target gene
specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha.
Mol Biol Cell. 18:4528–4542. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoon D, Pastore YD, Divoky V, Liu E,
Mlodnicka AE, Rainey K, Ponka P, Semenza GL, Schumacher A and
Prchal JT: Hypoxia-inducible factor-1 deficiency results in
dysregulated erythropoiesis signaling and iron homeostasis in mouse
development. J Biol Chem. 281:25703–25711. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dioum EM, Chen R, Alexander MS, Zhang Q,
Hogg RT, Gerard RD and Garcia JA: Regulation of hypoxia-inducible
factor 2alpha signaling by the stress-responsive deacetylase
sirtuin 1. Science. 324:1289–1293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
HolmquistMengelbier L, Fredlund E,
Löfstedt T, Noguera R, Navarro S, Nilsson H, Pietras A,
VallonChristersson J, Borg A, Gradin K, et al: Recruitment of
HIF-1alpha and HIF-2alpha to common target genes is differentially
regulated in neuroblastoma: HIF-2alpha promotes an aggressive
phenotype. Cancer Cell. 10:413–423. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Birle DC and Hedley DW: Suppression of the
hypoxia-inducible factor-1 response in cervical carcinoma
xenografts by proteasome inhibitors. Cancer Res. 67:1735–1743.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kallio PJ, Wilson WJ, O'Brien S, Makino Y
and Poellinger L: Regulation of the hypoxia-inducible transcription
factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem.
274:6519–6525. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ch'ng WC, Stanbridge EJ, Yusoff K and
Shafee N: The oncolytic activity of Newcastle disease virus in
clear cell renal carcinoma cells in normoxic and hypoxic
conditions: The interplay between VHL and interferon-β signaling. J
Interferon Cytokine Res. 33:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shinojima T, Oya M, Takayanagi A, Mizuno
R, Shimizu N and Murai M: Renal cancer cells lacking
hypoxia-inducible factor (HIF)-1alpha expression maintain vascular
endothelial growth factor expression through HIF-2alpha.
Carcinogenesis. 28:529–536. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Freeburg PB, Robert B, St John PL and
Abrahamson DR: Podocyte expression of hypoxia-inducible factor
(HIF)-1 and HIF-2 during glomerular development. J Am Soc Nephrol.
14:927–938. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yeo EJ, Cho YS, Kim MS and Park JW:
Contribution of HIF-1alpha or HIF-2alpha to erythropoietin
expression: In vivo evidence based on chromatin
immunoprecipitation. Ann Hematol. 87:11–17. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kaluz S, Kaluzová M and Stanbridge EJ:
Rational design of minimal hypoxia-inducible enhancers. Biochem
Biophys Res Commun. 370:613–618. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ema M, Taya S, Yokotani N, Sogawa K,
Matsuda Y and Fujii-Kuriyama Y: A novel bHLH-PAS factor with close
sequence similarity to hypoxia-inducible factor 1alpha regulates
the VEGF expression and is potentially involved in lung and
vascular development. Proc Natl Acad Sci U S A. 94:4273–4278. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carroll VA and Ashcroft M: Role of
hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the
regulation of HIF target genes in response to hypoxia, insulin-like
growth factor-I, or loss of von Hippel-Lindau function:
Implications for targeting the HIF pathway. Cancer Res.
66:6264–6270. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ratcliffe PJ: HIF-1 and HIF-2: Working
alone or together in hypoxia? J Clin Invest. 117:862–865. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Williams RD, Elliott AY, Stein N and
Fraley EE: In vitro cultivation of human renal cell cancer. I.
Establishment of cells in culture. Vitro. 12:623–627. 1976.
View Article : Google Scholar
|
|
25
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: Sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2011.PubMed/NCBI
|
|
26
|
Huang LE: Biochemistry. How HIF-1α handles
stress. Science. 339:1285–1286. 2013. View Article : Google Scholar : PubMed/NCBI
|
